Designed to degrade.
Engineered to repair
what is lost.
Akira Science develops programmable and bioresorbable biomaterials for soft tissue repair.
AkiMed™ is designed to provide temporary structural support, guide the healing process and safely resorb over time, promoting natural tissue healing.
For over 70 years, soft tissue repair has relied on the same biomaterials.
Soft tissue does not need stronger materials. It needs smarter ones, designed from the start for how soft tissue actually works.
First generation of absorbable biomaterials earned their place in medicine through sutures, drug delivery and bone repair. Then, the same materials were repurposed into soft tissue, and the mismatch began.
Soft tissue has different requirements: it flexes, moves and heals on its own time. Dissolve too soon, and you abandon healing tissue at its most vulnerable. Stay too long, and the body never stops reacting.
We started
differently.
Built from first principles
Chemistry, biology & mechanical performance
The Problem
Legacy Polymers
The Evolution
AkiMed™ Answer
01 Limitation
Biocompatibility risk
Legacy lactide-based materials degrade into acidic by-products, potentially contributing to inflammation and pain.
01 AkiMed Advantage
Built for pliability & safety
Porous scaffold architectures designed to provide temporary structure while respecting the mechanical environment of soft tissue.
02 Limitation
> 48 months degradation
Materials lose support too early or stay too long. PCL, for example, takes more than 4 years to resorb out of sync with soft-tissue repair timelines.
02 AkiMed Advantage
6–24 months programmed resorption
We design materials around different repair timelines, not the fixed behavior of off-the-shelf polymers. The material degrades safely without harmful by-products.
03 Limitation
Manufacturing limitations
Legacy biomaterials degrade while 3D-printing since they were not designed for it, limiting the design space for soft, patient-relevant architectures.
03 AkiMed Advantage
3D-printable and processable
Compatible with advanced and conventional polymer processing. A platform built for translation from polymer to implant which is stable up to 300 °C.
04 Limitation
Limited tissue integration
Legacy biomaterials are rigid, lack strength, and in most cases are unable to match the modulus of host tissue.
04 AkiMed Advantage
AkiMed™ tissue mimic
AkiMed is soft and flexible. Our technology combines novel chemistry with tissue-like architecture to mimic the mechanics of soft tissue.
THE PRODUCTS
Three divisions.One mission.
AkiMed™ is the foundation of a new class of biomaterial designed to restore what is lost. Our devices are how we deliver it to patients.
Available Now
AkiMed™ Biomaterial
- Pellets
- Filament for 3D-printing (Thermal stable >300 °C , diameter 1.75 mm)
- Microspheres
- 3D scaffolds
![AkiMed Breast Scaffold lattice](https://akirascience.com/wp-content/uploads/2026/05/Background-Akira_3.0.png")
In Preclinical Development
AkiMed™ Breast Scaffold
- First indication: Reconstruction after lumpectomy surgery
- Designed to preserve breast shape and volume
- Scaffold microstructure enables tissue integration and vascularization
In Preclinical Development
AkiMed™ Beyond Breast
- Potential use across human and animal applications
- Tailored properties from molecular level to final product
- Market entry points: injectable fillers, wound care, drug release, resorbable surgical devices
Three million women a year are diagnosed with breast cancer. Most survive thanks to early detection. Few are made whole again.
Existing reconstruction options were never designed for soft tissue — they were repurposed from sutures and orthopedic implants. The result is painful, multi-surgery procedures most patients can't access, leaving 91% with no option at all.
We are building the first family of bioresorbable biomaterials engineered specifically for soft-tissue regeneration. One implant, placed during the surgery the patient is already having, that guides her body to heal itself — then disappears.
3M
Women diagnosed with breast cancer annually
WHO · GLOBOCAN 2024
91%
Lumpectomy patients who receive no reconstruction
J. SURGICAL ONCOLOGY, 2020
2M
Lumpectomies performed worldwide each year
ISAPS · BCRF · ACS
1.8M
Addressable patients per year — our market
INTERNAL MODEL
What clinicians say.
The use of AkiMed™ could save approximately 55 minutes in a normal breast procedure. The device is simple to use, saves time and resources.
Antonio Piñero, MD PhD CEBS
President · Spanish Society Breast Disease
AkiMed™ has the potential to change the way we practice. No one desires implants that offer marginal improvements, nor does anyone wish for an unnecessary mastectomy.
Andreas Karakatsanis, MD PhD
Largest breast surgery unit · Sweden
Interested to pursue a clinical trial when AkiMed™ Breast Implant is ready to launch.
Sheldon M. Feldman, MD
Chief, Breast Surgery · Columbia University
I survived cancer. I just wanted to recognize myself in the mirror again.
— PATIENT TESTIMONY, COMPOSITE
A story behind every statistic
This is her story.
47. Mother of two. Six months post-lumpectomy.
The tumor was the size of a walnut. The surgery saved her life. The mirror didn’t give it back.
Her surgeon offered two paths: live with the deformity, or undergo a flap reconstruction — a second major surgery harvesting tissue from her abdomen, leaving a scar longer than the one on her breast.
She chose reconstruction. She is still healing. She was never offered a third option, because one did not exist.
The Healing Journey
One surgery. Lifetime solution.
-
Month 0
Lumpectomy + Place AkiMed™
Tumor is removed and AkiMed™ Breast Scaffold is placed in the space during the same surgery.
Month 0 -
Month 6
Month 6
Guided Tissue Ingrowth
Designed to allow native tissue ingrowth as the scaffold resorbs.
-
Month 12
Natural Volume Restoration
AkiMed™ Breast scaffold gradually degrades safely into water and CO₂.
Month 12
Investigational device. Illustrative timeline based on platform design targets.
AkiMed™ Breast Scaffold.
Design targets for AkiMed™ Breast. Investigational device — not yet cleared for clinical use.
THE TRACTION
One biomaterial family.
Multiple pathways to revenue.
Three granted patents. Seven peer-reviewed papers. Active EIC Pathfinder grant. Five signed LOIs and clinical interest from leaders at Columbia, Karolinska, Montefiore Einstein and beyond.
One polymer chemistry. Three physical formats.
The same biomaterial family is engineered into three distinct physical formats, each shaped to unlock a different indication while sharing one proven chemistry.
Granules
Technical and medical grade. Engineered for additive and conventional manufacturing techniques (e.g., injection molding, extrusion, electrospinning).
Filaments
For high-resolution 3D-printing (Filament Fused Filament, pellet-printing, bioprinting).
Microspheres
Small spherical particles with diameters typically in the micrometer to millimeter range.
Engineered for clinical territories and beyond.
Soft Tissue Repair
Mesh for void filling and tissue reinforcement (e.g., abdominal wall healing).
Biotech
RUO scaffolds tailored to support the development of cell and genetic therapies. (e.g., liver, pancreatic tissue models).
Aesthetic Medicine
Biostimulatory injectables for facial and body contouring.
Animal Health
Load-bearing architectures for surgical and sports-medicine indications where resorbability matters.
Drug Delivery
Microspheres with tunable degradation enables sustained, local release of biologics and small molecules.
Chronic Wound Care
Absorbable mesh engineered for diabetic ulcers and non-healing wounds. Sustained release of biologics guides re-epithelialisation and tissue integration.
Have an indication that needs a new format?
We bring the biomaterial, 3D-printing know-how, and device manufacturing. You bring the clinical insight.
The people
building this.
.
Álvaro Morales, PhD
CEO & Co-Founder
LinkedIn8+ years in 3D-printing for life sciences. PhD in Polymer Science. Co-inventor of 4 patents. Forbes 30 Under 30.
CEO
Ana Catarina Silva, PhD
COO & Co-Founder
LinkedIn15+ years in MedTech and diagnostics. Certified Board Member. Leads commercialization, go-to-market and partnerships.
COO
Veluska Bruce, PhD, MBA
CTO & Co-Founder
LinkedIn10 years in polymer-based medical devices. Expert in product portfolio growth, technical strategy and manufacturing.
CTO
Advisory Board
Antonio Piñero
Clinical · President Spanish Society Breast Disease
Andreas Karakatsanis
Clinical · Largest breast surgery unit, Sweden
Anna Finne Wistrand
Scientific · Professor KTH · Akira Founder
Krim Talia
Business · Serial entrepreneur, 2 IPOs
Anna Koptina
Regulatory · TOPRA Excellence 2024
Building a category.
Capital efficient.
Seed Stage. Unique biomaterial and 3D-printing technology platform, patented portfolio and licensing agreements to expand the use of AkiMed™. Convergence of impact, DeepTech and Women´s Health. For only breast reconstructive surgery, $1B addressable market. >92% gross margin at $3,500 ASP.
Álvaro Morales, PhD
CEO & Co-founder
alvaro@akirascience.com